| Drug Type AAV based gene therapy | 
| Synonyms recombinant adeno-associated virus 5 vector expressing a functional human cyclic nucleotide gated channel subunit beta 1 (CNGB1) gene (NIH/NCATS) | 
| Target | 
| Action modulators | 
| Mechanism CNGB1 modulators(cyclic nucleotide gated channel subunit beta 1 modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Retinitis Pigmentosa | Preclinical | United States  | 23 Sep 2024 | |
| Retinitis Pigmentosa | Preclinical | United States  | 23 Sep 2024 | 





